Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria

Journal of the Pediatric Infectious Diseases Society

Volumn 6, Issue 2, 2017, Pages 123-128

  Iosifidis, Elias ^a   Violaki, Asimenia ^a   Michalopoulou, Evangelia ^a   Volakli, Elena ^a   Diamanti, Elisavet ^a   Koliouskas, Dimitrios ^b   Antachopoulos, Charalampos ^a   Drossou Agakidou, Vasiliki ^a   Sdougka, Maria ^a   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Critically ill children; Extensive drug resistance; Gram negative bacteria; Healthcare associated infections; Tigecycline

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM; CEPHALOSPORIN; COLISTIN; COTRIMOXAZOLE; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ACUTE PANCREATITIS; ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CHILD; CLINICAL ARTICLE; CLINICAL OUTCOME; CRITICALLY ILL PATIENT; FEMALE; GRAM NEGATIVE BACTERIUM; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL MORTALITY; HUMAN; INFANT; INFECTION; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MAINTENANCE DRUG DOSE; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPSIS; SERRATIA MARCESCENS; VOMITING; ANALOGS AND DERIVATIVES; CROSS INFECTION; DRUG EFFECTS; GRAM NEGATIVE INFECTION; MICROBIOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; MINOCYCLINE; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85020913194     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piw009     Document Type: Article

References (30)

1. Glasner C, Albiger B, Buist G, et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013; 18.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
3. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
4. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis 2014; 58:1439-48.
5. Patel SJ, O'Toole D, Larson E. A new metric of antibiotic class resistance in Gram-negative bacilli isolated from hospitalized children. Infect Control Hosp Epidemiol 2012; 33:602-7.
6. Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J Infect 2009; 58:273-84.
7. Folgori L, Livadiotti S, Carletti M, et al. Epidemiology and clinical outcomes of multidrug-resistant Gram-negative bloodstream infections in a European tertiary pediatric hospital during a 12-month period. Pediatr Infect Dis J 2014; 33:929-32.
8. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115:942-9.
9. Maltezou HC, Kontopidou F, Katerelos P, et al. Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children. Pediatr Infect Dis J 2013; 32:e151-4.
10. Lin YS, Hung MH, Chen CC, et al. Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: case report in a child. J Microbiol Immunol Infect 2016; 49:138-41.
11. Ozdemir H, Ciftci E, Karbuz A, et al. Successful treatment of multidrug-resistant Escherichia coli bacteremia with tigecycline in an acute myeloid leukemia child. Turk J Pediatr 2012; 54:59-60.
12. Hurtado IC, Trujillo M, Restrepo A, et al. [Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae]. Rev Chilena Infectol 2012; 29:317-21.
13. Bassetti M, Poulakou G, Giamarellou H. Is there a future for tigecycline? Intensive Care Med 2014; 40:1039-45.
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
15. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. Available at: http://www.fda.gov/drugs/drugsafety/ ucm369580.htm. Accessed 2 January 2016.
16. European Medicines Agency. Tigecycline, Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/000644/WC500044508.pdf. Accessed 3 January 2016.
17. Falagas ME, Vardakas KZ, Tsiveriotis KP, et al. Effectiveness and safety of highdose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014; 44:1-7.
18. De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014; 18:R90.
19. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34:496-507e1.
20. Dinleyici EC, Yargic ZA, Bor O, et al. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 55:349-51.
21. Du X, Fu Y, Yu Y. Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient. Ann Clin Microbiol Antimicrob 2013; 12:19.
22. Green DA, Srinivas N, Watz N, et al. A pediatric case of New Delhi metallo-beta-lactamase-1-producing Enterobacteriaceae in the United States. Pediatr Infect Dis J 2013; 32:1291-4.
23. De Luca M, Angelino G, Calo Carducci FI, et al. Multidrug-resistant Acinetobacter baumannii infection in children. BMJ Case Rep 2011; 2011.
24. Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2010; 29:379-81.
25. Prot-Labarthe S, Youdaren R, Benkerrou M, et al. Pediatric acute pancreatitis related to tigecycline. Pediatr Infect Dis J 2010; 29:890-1.
26. Maximova N, Zanon D, Verzegnassi F, Granzotto M. Neutrophils engraftment delay during tigecycline treatment in 2 bone marrow-transplanted patients. J Pediatr Hematol Oncol 2013; 35:e33-7.
27. Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57:1756-62.
28. Routsi C, Kokkoris S, Douka E, et al. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents 2015; 45:90-3.
29. Mouloudi E, Massa E, Piperidou M, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc 2014; 46:3219-21.
30. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPCproducing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70:2133-43.